On August 1, 2025, the JPML reported there are 2,190 cases pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Novo Nordisk has struggled in the US market this year: It was slow to introduce a direct-to-consumer sales platform, and competitors rolled out cheaper Ozempic copycats
Versus other research peptides Compounds like AOD-9604 use different mechanisms and dosing schedules, highlighting the importance of compound-specific protocols
Furthermore, in its bark has been determined that lupeol, acacetin phenylpropan hit acids, antioxidants and cytotoxic are responsible (Vilela et al., 2021)
doi:10.1186/s13229-016-0088-6 14 Radomska-Leniewska, D